Kenneth J. Bender, PharmD, MA

July 24, 2024

Based on guidance from the American Society of Preventive Cardiology, this topline summarizes risk factors and interventions to reduce the risk of major adverse CV events.

July 22, 2024

Click through this topline on primordial and primary CVD prevention based on the American Society of Preventive Cardiology's clinical practice statement.

June 19, 2024

For primary care clinicians, this Guideline Topline provides a summary of 2024 ADA Standard of Care updates that may support improved outcomes in your practice.

February 09, 2024

Get GOLD Report updates at-a-glance on initiating pharmacotherapy, avoiding exacerbations, treating dyspnea, how to approach using ICS, plus other topics.

September 27, 2023

The 2022 AAFP Clinical Practice Guideline on hypertension treatment in adults is the subject matter for this 10-question topline quiz that is also a good source of review.

April 20, 2023

Use of opioids to manage chronic pain is not preferred but the VA/DoD make specific new recommendations on how to proceed. Try 8 questions on the guidelines.

July 26, 2019

One US researcher notes that using A1c alone to classify diabetes may misdiagnose >33 million Americans. What are the other options and how well do they work? Read on.

June 25, 2019

ADA 2019 ICYMI: Tirzepatide, a GIP and GLP-1 receptor agonist, reduces A1c and BMI as well as biomarkers of metabolic dysfunction in type 2 diabetes patients. Four studies reviewed.

June 25, 2019

ADA 2019 ICYMI: Safety and efficacy of oral semaglutide in patients with T2DM was demonstrated in results of 3 PIONEER program clinical trials.  Highlights, here.

June 17, 2019

ADA 2019--Linagliptin, the DPP-4 inhibitor, showed similar risk for first or recurrent CV events or hopspitalization vs placebo in T2DM patients with high cardiorenal risk in CARMELINA subanalysis.